Skip to content
yes i take peptides.
Library/For Cognition/Cerebrolysin
Rx in EU/AsiaFor Cognition+2 more

Cerebrolysin

A porcine brain-derived peptide preparation, used in stroke and dementia care across Europe and Asia for decades. We read all 60 studies. The protocol is below.

Updated 03 May 2026Read 14 minEvidence ●●●○○Citations 60
+ Add to Stack
⚖ Compare side-by-side⎙ Print companion card

Free — puts Cerebrolysin on your decision board.

The Cerebrolysin Report · $19

Everything you need to start: dose, sourcing, safety, our verdict.

One purchase · yours forever

Built from 60 cited studies.

Status
Rx
Class
For Cognition
Evidence
3/ 5●●●○○
Approved in
$19 ↓
FDA-approved
$19 ↓
Phase 3 RCTs
$19 ↓
Read this if
  • you have a parent recovering from a stroke and the rehab plateau is real
  • you had a concussion that hasn't fully resolved
  • you grew up in a country where this was just what the neurologist gave grandma
  • **route reality** — the trials are **IV infusion (drip) in a clinic**, not self-injected at home. Importers who self-inject IM into a glute are not running the trial protocol
Skip this if
  • you want clean US-trial data — most of the evidence is from Eastern Europe
  • you're shopping for a "smart drug" without a specific neurological event — this is a **defined 10–20 day course tied to an event** (stroke, TBI), not a chronic stack
  • you have a known allergy to porcine-derived products or are pregnant — Cerebrolysin is a porcine brain hydrolysate
  • you're vegetarian/vegan or have a religious restriction on porcine products — there is no alternative source
The 4 ways you can buy Cerebrolysin
Brand
✓
Rx in EU/Asia
$120–$220/course at EU retail (US import restricted)
Real product. Most-trialed peptide in this batch but not legally available to US patients.
Compounded 503A
✗
Not available
503A pharmacies cannot synthesize undefined biologic mixtures; brand or medical tourism are the on…
RUO (research-only)
✓
Sold 'for research only'
Rarely sold; identity unverifiable
The brand is a defined manufacturing process, not a single molecule — 'RUO Cerebrolysin' is functi…
Gray market
✓
Unregulated overseas import
Varies — not on user's vendor list
Gray-market peptide vendors do not carry biologics. Practical cheap path is medical tourism (real …
Click any lane for the full Sourcing breakdown.
First 90 days · Cerebrolysin
Weeks 1–2
Subjective signal in the first 1–2 weeks if there's going to be one. Cognitive peptides (Selank, Semax) work fast or not at all for a given person.
Weeks 4–8
Either you've noticed a clear, consistent improvement (focus, anxiety reduction, mood stability) or you're imagining it. Track a baseline cognitive task or anxiety scale if you can.
Week 12 — decide
Decide. Cognitive effects are notoriously subject to placebo. If the signal isn't holding without you actively looking for it, it's probably not real.
Quit if
  • Paradoxical anxiety, agitation, or sleep disruption.
  • Two-week proper-dose trial with no perceived benefit.
  • Mood destabilization in either direction.
Identity

What it is.

Cerebrolysin is *not* a single . It's a mixture of low-molecular-weight peptides and free amino acids derived from enzymatically processed porcine brain tissue. Manufactured by Ever Pharma in Austria, it's been on the market in Europe, Asia, and parts of South America since the 1970s for stroke, traumatic brain injury, vascular dementia, and Alzheimer's disease.

It's not approved by the FDA. It's also not a research chemical — it's a real prescription drug in dozens of countries, just not the United States. The standard route of administration is intravenous infusion, daily for several weeks, in a clinical setting. Off-label users in the US import it and self-inject intramuscularly, which is not how it was studied.

The proposed mechanism centers on neurotrophic mimicry — the fragments are thought to mimic endogenous neurotrophic factors like BDNF and NGF, supporting neuronal survival and synaptic plasticity. The actual mix is poorly characterized.

TL;DR

TL;DR. 30-second version.

The compressed verdict — what Cerebrolysin actually is, what the human evidence shows, and the watch-for in three bullets. Locked.

Get the report · $19 ↓
Mechanism

Mechanism.

Mechanism · in the Cerebrolysin report

How the molecule actually works — receptor profile, downstream signaling, what to expect mechanistically.

Get the report · $19 ↓
Evidence

Evidence. What we actually know in humans.

Evidence · in the Cerebrolysin report

The trial breakdown — phase, n, primary endpoint, who funded, what hit, what didn't.

Get the report · $19 ↓
Human-Evidence Factbox
Approved in
$19 ↓
FDA-approved
$19 ↓
Phase 3 RCTs
$19 ↓
Cochrane reviews
$19 ↓
Years in clinical use
$19 ↓
Major adverse events flagged
$19 ↓
Dose

Dose. The actual protocol.

Dose · in the Cerebrolysin report

The specific protocol — dose, titration schedule, cycle pattern, frequency, route.

We read 60 studies to write this report.
Get the report · $19 ↓
Sourcing

Sourcing. Where the cohort actually buys.

Sourcing · in the Cerebrolysin report

Sourcing breakdown — vendor methodology, red flags, our published test results, COA checklist.

We read 60 studies to write this report.
Get the report · $19 ↓
Safety

Safety. Side effects.

Safety · in the Cerebrolysin report

The watch-for list — contraindications, drug interactions, monitoring labs, when to stop.

Get the report · $19 ↓
Editorial Position

Editorial position.

Editorial Position · in the Cerebrolysin report

Our editorial position — explicit yes / no / depends, with the reasoning behind it.

Get the report · $19 ↓
Citations

Citations.

  1. 01Ziganshina LE, et al. Cerebrolysin for acute ischaemic stroke. The Cochrane database of systematic reviews. 2023;10(10):CD007026. PMID: 37818733.
  2. 02Cui S, et al. Cerebrolysin for vascular dementia. The Cochrane database of systematic reviews. 2019;2019(11). PMID: 31710397.
  3. 03Ziganshina LE, et al. Cerebrolysin for acute ischaemic stroke. The Cochrane database of systematic reviews. 2020;7(7):CD007026. PMID: 32662068.
  4. 04Ziganshina LE, et al. Cerebrolysin for acute ischaemic stroke. The Cochrane database of systematic reviews. 2017;4(4):CD007026. PMID: 28430363.
  5. 05Brainin M. Cerebrolysin: a multi-target drug for recovery after stroke. Expert review of neurotherapeutics. 2018;18(8):681-687. PMID: 30004268.
+Show all 60 citations
  1. 06Ziganshina LE, et al. Cerebrolysin for acute ischaemic stroke. The Cochrane database of systematic reviews. 2015(6):CD007026. PMID: 26083192.
  2. 07Chen N, et al. Cerebrolysin for vascular dementia. The Cochrane database of systematic reviews. 2013(1):CD008900. PMID: 23440834.
  3. 08Ozkizilcik A, et al. Nanodelivery of cerebrolysin reduces pathophysiology of Parkinson's disease. Progress in brain research. 2019;245:201-246. PMID: 30961868.
  4. 09Fiani B, et al. Cerebrolysin for stroke, neurodegeneration, and traumatic brain injury: review of the literature and outcomes. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2021;42(4):1345-1353. PMID: 33515100.
  5. 10Plosker GL, et al. Cerebrolysin: a review of its use in dementia. Drugs & aging. 2009;26(11):893-915. PMID: 19848437.
  6. 11Vester JC, et al. Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2021;42(11):4531-4541. PMID: 33620612.
  7. 12Kalinin MN, et al. [Cerebrolysin as an early add-on to reperfusion therapy: heterogeneous treatment effect analysis in ischemic stroke patients with varying risk of hemorrhagic transformation]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2024;124(3. Vyp. 2):55-66. PMID: 38512096.
  8. 13Ziganshina LE, et al. Cerebrolysin for acute ischaemic stroke. The Cochrane database of systematic reviews. 2010(4):CD007026. PMID: 20393954.
  9. 14Ziganshina LE, et al. Cerebrolysin for acute ischaemic stroke. The Cochrane database of systematic reviews. 2016;12(12):CD007026. PMID: 27918088.
  10. 15iganshina LE, et al. [Cerebrolysin for acute ischemic stroke]. Vestnik Rossiiskoi akademii meditsinskikh nauk. 2013(1):21-9. PMID: 23805635.
  11. 16Gavrilova SI, et al. Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer's disease: 30 years of clinical use. Medicinal research reviews. 2021;41(5):2775-2803. PMID: 32808294.
  12. 17Torshin IY, et al. [Cerebrolysin peptides as mood stabilizers]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2019;119(12):69-75. PMID: 31994517.
  13. 18Gauthier S, et al. Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials. Dementia and geriatric cognitive disorders. 2015;39(5-6):332-47. PMID: 25832905.
  14. 19Wang Z, et al. Cerebrolysin for functional recovery in patients with acute ischemic stroke: a meta-analysis of randomized controlled trials. Drug design, development and therapy. 2017;11:1273-1282. PMID: 28458521.
  15. 20Bogolepova AN. [Cerebrolysin in the treatment of cognitive impairment]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2023;123(3):20-25. PMID: 36946392.
  16. 21Villarreal-Reyna G, et al. Cerebrolysin induces hair repigmentation associated to MART-1/Melan-A reactivation. European journal of medical research. 2022;27(1):257. PMID: 36411485.
  17. 22Allegri RF, et al. Cerebrolysin improves symptoms and delays progression in patients with Alzheimer's disease and vascular dementia. Drugs of today (Barcelona, Spain : 1998). 2012;48 Suppl A:25-41. PMID: 22514793.
  18. 23Fiani B, et al. Neuroprotective strategies of cerebrolysin for the treatment of infants with neonatal hypoxic-ischemic encephalopathy. Acta neurologica Belgica. 2021;121(6):1401-1406. PMID: 34494216.
  19. 24Sharma A, et al. Nanowired Delivery of Cerebrolysin Together with Antibodies to Amyloid Beta Peptide, Phosphorylated Tau, and Tumor Necrosis Factor Alpha Induces Superior Neuroprotection in Alzheimer's Disease Brain Pathology Exacerbated by Sleep Deprivation. Advances in neurobiology. 2023;32:3-53. PMID: 37480458.
  20. 25Sharma HS, et al. Nanowired delivery of cerebrolysin with neprilysin and p-Tau antibodies induces superior neuroprotection in Alzheimer's disease. Progress in brain research. 2019;245:145-200. PMID: 30961867.
  21. 26Homberg V, et al. Speech Therapy Combined With Cerebrolysin in Enhancing Nonfluent Aphasia Recovery After Acute Ischemic Stroke: ESCAS Randomized Pilot Study. Stroke. 2025;56(4):937-947. PMID: 39957612.
  22. 27Staszewski J, et al. Efficacy of Cerebrolysin Treatment as an Add-On Therapy to Mechanical Thrombectomy in Patients with Acute Ischemic Stroke Due to Large Vessel Occlusion in Anterior Circulation: Results of a 3-Month Follow-up of a Prospective, Open Label, Single-Center Study. Translational stroke research. 2025;16(6):1931-1946. PMID: 40325343.
  23. 28Menon PK, et al. Cerebrolysin, a mixture of neurotrophic factors induces marked neuroprotection in spinal cord injury following intoxication of engineered nanoparticles from metals. CNS & neurological disorders drug targets. 2012;11(1):40-9. PMID: 22229324.
  24. 29Sarode LP, et al. Cerebrolysin reduces excitotoxicity by modulation of cell-death proteins in delayed hours of ischemic reperfusion injury. Metabolic brain disease. 2023;38(7):2401-2416. PMID: 37273080.
  25. 30Rejdak K, et al. Modulation of neurotrophic factors in the treatment of dementia, stroke and TBI: Effects of Cerebrolysin. Medicinal research reviews. 2023;43(5):1668-1700. PMID: 37052231.
  26. 31Tonge C, et al. Cerebrolysin Amelioration of Spinal Cord Ischemia/ Reperfusion Injury in Rabbit Model. Turkish neurosurgery. 2023;33(6):1017-1027. PMID: 37309634.
  27. 32Wan M, et al. Efficacy, safety, and cost-effectiveness analysis of Cerebrolysin in acute ischemic stroke: A rapid health technology assessment. Medicine. 2024;103(13):e37593. PMID: 38552072.
  28. 33Kojder K, et al. Cerebrolysin in Patients Diagnosed with Subarachnoid Hemorrhage-The Results of an Observational Cohort Study. Biomedicines. 2024;12(11). PMID: 39595058.
  29. 34Al-Kuraishy HM, et al. The possible role of cerebrolysin in the management of vascular dementia: Leveraging concepts. Neuroscience. 2025;568:202-208. PMID: 39832667.
  30. 35Thome J, et al. Safety profile of Cerebrolysin: clinical experience from dementia and stroke trials. Drugs of today (Barcelona, Spain : 1998). 2012;48 Suppl A:63-9. PMID: 22514795.
  31. 36Sharma HS, et al. Neuroprotective Effects of Nanowired Delivery of Cerebrolysin with Mesenchymal Stem Cells and Monoclonal Antibodies to Neuronal Nitric Oxide Synthase in Brain Pathology Following Alzheimer's Disease Exacerbated by Concussive Head Injury. Advances in neurobiology. 2023;32:139-192. PMID: 37480461.
  32. 37Bornstein NM, et al. Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2018;39(4):629-640. PMID: 29248999.
  33. 38Zhang D, et al. Efficacy and Safety of Cerebrolysin for Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled Trials. BioMed research international. 2017;2017:4191670. PMID: 28656143.
  34. 39Alzoubi KH, et al. Cerebrolysin prevents sleep deprivation induced memory impairment and oxidative stress. Physiology & behavior. 2020;217:112823. PMID: 31987894.
  35. 40Antón Álvarez X, et al. Cerebrolysin in Alzheimer's disease. Drugs of today (Barcelona, Spain : 1998). 2011;47(7):487-513. PMID: 22013558.
  36. 41Strilciuc S, et al. Cost-effectiveness of Cerebrolysin as an add-on treatment for neurorecovery after traumatic brain injury. Journal of medicine and life. 2025;18(4):387-392. PMID: 40405935.
  37. 42Abdelaty AO, et al. Cerebrolysin potentiates the antidepressant effect of lithium in a rat model of depression. Journal of psychiatric research. 2024;172:171-180. PMID: 38394763.
  38. 43Ozkizilcik A, et al. Nanowired delivery of antibodies to tau and neuronal nitric oxide synthase together with cerebrolysin attenuates traumatic brain injury induced exacerbation of brain pathology in Parkinson's disease. International review of neurobiology. 2023;171:83-121. PMID: 37783564.
  39. 44Yazar U, et al. Cerebrolysin provides effective protection on high glucose-induced neuropathy in cultured rat dorsal root ganglion neurons. Journal of receptor and signal transduction research. 2023;43(5):109-114. PMID: 38079610.
  40. 45Guekht A, et al. Safety and efficacy of Cerebrolysin in motor function recovery after stroke: a meta-analysis of the CARS trials. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2017;38(10):1761-1769. PMID: 28707130.
  41. 46Sharma HS, et al. Alzheimer's disease: cerebrolysin and nanotechnology as a therapeutic strategy. Neurodegenerative disease management. 2016;6(6):453-456. PMID: 27827552.
  42. 47Wei ZH, et al. Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer's disease. Journal of neural transmission (Vienna, Austria : 1996). 2007;114(5):629-34. PMID: 17318304.
  43. 48Wiklund L, et al. TiO(2)-Nanowired Delivery of Chinese Extract of Ginkgo biloba EGb-761 and Bilobalide BN-52021 Enhanced Neuroprotective Effects of Cerebrolysin Following Spinal Cord Injury at Cold Environment. Advances in neurobiology. 2023;32:353-384. PMID: 37480466.
  44. 49Khasanova DR, et al. Cerebrolysin as an Early Add-on to Reperfusion Therapy: Risk of Hemorrhagic Transformation after Ischemic Stroke (CEREHETIS), a prospective, randomized, multicenter pilot study. BMC neurology. 2023;23(1):121. PMID: 36973684.
  45. 50Kang DH, et al. Effects of Cerebrolysin on Hippocampal Neuronal Death After Pilocarpine-Induced Seizure. Frontiers in neuroscience. 2020;14:568813. PMID: 33177978.
  46. 51Mafikandi V, et al. Effects of cerebrolysin on behavioral changes and the tryptophan-kynurenine pathway in the prefrontal cortex of male mice in the ketamine model of schizophrenia. Molecular biology reports. 2025;52(1):723. PMID: 40668305.
  47. 52Muresanu DF, et al. Diabetes exacerbates brain pathology following a focal blast brain injury: New role of a multimodal drug cerebrolysin and nanomedicine. Progress in brain research. 2020;258:285-367. PMID: 33223037.
  48. 53Sharma A, et al. Sleep deprivation exacerbates concussive head injury induced brain pathology: Neuroprotective effects of nanowired delivery of cerebrolysin with α-melanocyte-stimulating hormone. Progress in brain research. 2019;245:1-55. PMID: 30961865.
  49. 54Zhang Y, et al. Cerebrolysin Reduces Astrogliosis and Axonal Injury and Enhances Neurogenesis in Rats After Closed Head Injury. Neurorehabilitation and neural repair. 2019;33(1):15-26. PMID: 30499355.
  50. 55Martínez-Torres NI, et al. Cerebrolysin Induces Motor Recovery Along with Plastic Changes in Motoneurons and an Increase in GAP43 Protein in the Ventral Spinal Cord Following a Kainic Acid Excitotoxic Lesion in the Rat Motor Cortex. Neurochemical research. 2024;50(1):31. PMID: 39580783.
  51. 56Aguilar-Hernández L, et al. Cerebrolysin ameliorates prefrontal cortex and hippocampus neural atrophy of spontaneous hypertensive rats with hyperglycemia. Synapse (New York, N.Y.). 2020;74(9):e22156. PMID: 32232874.
  52. 57Sharma HS, et al. Alzheimer's disease neuropathology is exacerbated following traumatic brain injury. Neuroprotection by co-administration of nanowired mesenchymal stem cells and cerebrolysin with monoclonal antibodies to amyloid beta peptide. Progress in brain research. 2021;265:1-97. PMID: 34560919.
  53. 58Ponomareva EV, et al. [Cerebrolysin in the preventive therapy of dementia in elderly patients with mild cognitive impairment: a three-year prospective comparative study]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2024;124(9):51-59. PMID: 39435777.
  54. 59Sharma A, et al. Mild traumatic brain injury exacerbates Parkinson's disease induced hemeoxygenase-2 expression and brain pathology: Neuroprotective effects of co-administration of TiO(2) nanowired mesenchymal stem cells and cerebrolysin. Progress in brain research. 2020;258:157-231. PMID: 33223035.
  55. 60Selezneva ND, et al. [Cerebrolysin Treatment Reduces the Risk of Mild Cognitive Decline to Dementia in 1st-Degree Relatives of Alzheimer's Patients: A Prospective Comparative Study]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2023;123(8):90-97. PMID: 37655416.
The Cerebrolysin Report · $19

Everything you need to start.

Dose, sourcing, safety, our verdict. One purchase. Yours forever.

Built from 60 cited studies.

Or get every report. All reports — $99 once · Pro — $29/mo.
Compare tiers →